FDA to Collaborate with ACD/Labs to Develop Predictive QSAR Models
“We are excited to work with the FDA on this project,” said Tim Blacker, Director of Business Development and Strategic Alliances at ACD/Labs. “This effort will leverage the combined expertise of scientists at both ACD/Labs and the FDA to produce software that will provide value to the FDA and to the safety of the wider community in general.”
As part of this agreement, results of this collaboration will be made available to the public via publications and presentations.
About ACD/Labs—Founded in 1994, Advanced Chemistry Development, Inc., (ACD/Labs) has since supplied hundreds of industrial companies and academic organizations worldwide with software to speed research. Our solutions include fast and accurate prediction of molecular ADME/Tox and physical properties, property-based structure design, metabolite identification, analytical data processing and interpretation, chemical nomenclature, and chemical databasing. ACD/Labs is committed to ongoing development and improvement of its products, constantly improving the accuracy and usability of existing functionality, while also delivering exciting and innovative new capabilities aimed at solving customers’ challenges. http://www.acdlabs.com/